Pediatric Neuro-oncology.

Journal

Continuum (Minneapolis, Minn.)

ISSN: 1538-6899

Titre abrégé: Continuum (Minneap Minn)

Pays: United States

ID NLM: 9509333

Informations de publication

Date de publication:
01 Dec 2023

Historique:

medline: 12 12 2023

pubmed: 12 12 2023

entrez: 12 12 2023

Statut: ppublish

Résumé

This article reviews the most common pediatric brain tumors, neurocutaneous syndromes, treatment-related neurotoxicities, and the long-term outcomes of survivors. In the era of molecular diagnostics, the classification, management, and prognostication of pediatric brain tumors and neurocutaneous syndromes has been refined, resulting in advancements in patient management. Molecular diagnostics have been incorporated into the most recent World Health Organization 2021 classification. This knowledge has allowed for novel therapeutic approaches targeting the biology of these tumors with the intent to improve overall survival, decrease treatment-related morbidity, and improve quality of life. Advances in management have led to better survival, but mortality remains high and significant morbidity persists. Current clinical trials focus on tumor biology targeted therapy, deescalation of therapy, and multimodal intensified approaches with targeted therapy in more high-risk tumors. Molecular diagnostics for pediatric brain tumors and neurocutaneous syndromes have led to novel therapeutic approaches targeting the biology of these tumors with the goals of improving overall survival and decreasing treatment-related morbidity. Further understanding will lead to continued refinement and improvement of tumor classification, management, and prognostication.

Identifiants

DOI: 10.1212/CON.0000000000001360 PMID: 38085894

pubmed: 38085894

doi: 10.1212/CON.0000000000001360

pii: 00132979-202312000-00006

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

1680-1709

Informations de copyright

Références

Ostrom QT, Price M, Ryan K, et al. CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro-Oncol 2022;24(Suppl 3):iii1–iii38. doi:10.1093/neuonc/noac161

doi: 10.1093/neuonc/noac161

Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. Neuro-Oncol 2019;21(11):1357–1375. doi:10.1093/neuonc/noz123

doi: 10.1093/neuonc/noz123

Jaimes C, Poussaint TY. Primary neoplasms of the pediatric brain. Radiol Clin North Am 2019;57(6):1163–1175. doi:10.1016/j.rcl.2019.06.004

doi: 10.1016/j.rcl.2019.06.004

Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 2020;8(1):30. doi:10.1186/s40478-020-00902-z

doi: 10.1186/s40478-020-00902-z

Chamdine O, Broniscer A, Wu S, Gajjar A, Qaddoumi I. Metastatic low-grade gliomas in children: 20 years’ experience at St. Jude Children’s Research Hospital. Pediatr Blood Cancer 2016;63(1):62–70. doi:10.1002/pbc.25731

doi: 10.1002/pbc.25731

Bornhorst M, Frappaz D, Packer RJ. Pilocytic astrocytomas. Handb Clin Neurol 2016;134:329–344. doi:10.1016/B978-0-12-802997-8.00020-7

doi: 10.1016/B978-0-12-802997-8.00020-7

Shaikh N, Brahmbhatt N, Kruser TJ, et al. Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol 2019;8(3):CNS39. doi:10.2217/cns-2019-0009

doi: 10.2217/cns-2019-0009

Collins KL, Pollack IF. Pediatric low-grade gliomas. Cancers 2020;12(5):1152. doi:10.3390/cancers12051152

doi: 10.3390/cancers12051152

de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr 2019;31(1):21–27. doi:10.1097/MOP.0000000000000717

doi: 10.1097/MOP.0000000000000717

Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am 2019;103(6):1035–1054. doi:10.1016/j.mcna.2019.07.004

doi: 10.1016/j.mcna.2019.07.004

Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of Neurofibromatosis type 1. Acta Neuropathol (Berl) 2020;139(4):625–641. doi:10.1007/s00401-019-02002-2

doi: 10.1007/s00401-019-02002-2

Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2017;59(11):1112–1116. doi:10.1111/dmcn.13526

doi: 10.1111/dmcn.13526

Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011

doi: 10.1016/j.pediatrneurol.2021.07.011

Diagnosis, surveillance, and management. TSC Alliance. Accessed October 30, 2023. https://www.tscalliance.org/healthcare-professionals/diagnosis/

Islam MP. Tuberous sclerosis complex. Semin Pediatr Neurol 2021;37:100875. doi:10.1016/j.spen.2021.100875

doi: 10.1016/j.spen.2021.100875

de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis 2018;13(1):157. doi:10.1186/s13023-018-0901-8

doi: 10.1186/s13023-018-0901-8

Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and legius syndrome: an international consensus recommendation. Genet Med Off J Am Coll Med Genet 2021;23(8):1506–1513. doi:10.1038/s41436-021-01170-5

doi: 10.1038/s41436-021-01170-5

Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. Hum Genet 2022;141(2):177–191. doi:10.1007/s00439-021-02410-z

doi: 10.1007/s00439-021-02410-z

Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 2017;32(4):520–537.e5. doi:10.1016/j.ccell.2017.08.017

doi: 10.1016/j.ccell.2017.08.017

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106

doi: 10.1093/neuonc/noab106

Fangusaro J, Bandopadhayay P. Advances in the classification and treatment of pediatric brain tumors. Curr Opin Pediatr 2021;33(1):26–32. doi:10.1097/MOP.0000000000000975

doi: 10.1097/MOP.0000000000000975

Jones C, Karajannis MA, Jones DTW, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncol 2017;19(2):153–161. doi:10.1093/neuonc/now101

doi: 10.1093/neuonc/now101

Coleman C, Stoller S, Grotzer M, et al. Pediatric hemispheric high-grade glioma: targeting the future. Cancer Metastasis Rev 2020;39(1):245–260. doi:10.1007/s10555-020-09850-5

doi: 10.1007/s10555-020-09850-5

Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D. Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol 2017;134(3):541–549. doi:10.1007/s11060-017-2393-0

doi: 10.1007/s11060-017-2393-0

Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li-fraumeni syndrome. Clin Cancer Res Off J Am Assoc Cancer Res 2017;23(11):e38–e45. doi:10.1158/1078-0432.CCR-17-0408

doi: 10.1158/1078-0432.CCR-17-0408

Aronson M, Colas C, Shuen A, et al. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the International Consensus Working Group. J Med Genet 2022;59(4):318–327. doi:10.1136/jmedgenet-2020-107627

doi: 10.1136/jmedgenet-2020-107627

Durno C, Boland CR, Cohen S, et al. Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017;152(6):1605–1614. doi:10.1053/j.gastro.2017.02.011

doi: 10.1053/j.gastro.2017.02.011

Yurgelun MB, Hampel H. Recent advances in lynch syndrome: diagnosis, treatment, and cancer prevention. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 2018;38:101–109. doi:10.1200/EDBK_208341

doi: 10.1200/EDBK_208341

Michaeli O, Tabori U. Pediatric high grade gliomas in the context of cancer predisposition syndromes. J Korean Neurosurg Soc 2018;61(3):319–332. doi:10.3340/jkns.2018.0031

doi: 10.3340/jkns.2018.0031

Williams JR, Young CC, Vitanza NA, et al. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care. Neurosurg Focus 2020;48(1):E4. doi:10.3171/2019.9.FOCUS19745

doi: 10.3171/2019.9.FOCUS19745

Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol Off J Am Soc Clin Oncol 2018;36(19):1963–1972. doi:10.1200/JCO.2017.75.9308

doi: 10.1200/JCO.2017.75.9308

Freese C, Takiar V, Fouladi M, et al. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol 2017;7(2):86–92. doi:10.1016/j.prro.2016.11.005

doi: 10.1016/j.prro.2016.11.005

Veldhuijzen van Zanten SEM, Cruz O, Kaspers GJL, et al. State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature. J Neurooncol 2016;128(3):387–394. doi:10.1007/s11060-016-2141-x

doi: 10.1007/s11060-016-2141-x

Northcott PA, Robinson GW, Kratz CP, et al. Medulloblastoma. Nat Rev Dis Primer 2019;5(1):11. doi:10.1038/s41572-019-0063-6

doi: 10.1038/s41572-019-0063-6

Warren KE, Vezina G, Poussaint TY, et al. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the response assessment in Pediatric Neuro-oncology Committee. Neuro-Oncol 2018;20(1):13–23. doi:10.1093/neuonc/nox087

doi: 10.1093/neuonc/nox087

Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol (Berl) 2016;131(6):821–831. doi:10.1007/s00401-016-1569-6

doi: 10.1007/s00401-016-1569-6

Skowron P, Farooq H, Cavalli FMG, et al. The transcriptional landscape of Shh medulloblastoma. Nat Commun 2021;12(1):1749. doi:10.1038/s41467-021-21883-0

doi: 10.1038/s41467-021-21883-0

Khan RB, Patay Z, Klimo P, et al. Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. Neuro-Oncol 2021;23(9):1586–1596. doi:10.1093/neuonc/noab030

doi: 10.1093/neuonc/noab030

Pols SYCV, van Veelen MLC, Aarsen FK, Gonzalez Candel A, Catsman-Berrevoets CE. Risk factors for development of postoperative cerebellar mutism syndrome in children after medulloblastoma surgery. J Neurosurg Pediatr 2017;20(1):35–41. doi:10.3171/2017.2.PEDS16605

doi: 10.3171/2017.2.PEDS16605

Albazron FM, Bruss J, Jones RM, et al. Pediatric postoperative cerebellar cognitive affective syndrome follows outflow pathway lesions. Neurology 2019;93(16):e1561–e1571. doi:10.1212/WNL.0000000000008326

doi: 10.1212/WNL.0000000000008326

Wickenhauser ME, Khan RB, Raches D, et al. Characterizing posterior fossa syndrome: a survey of experts. Pediatr Neurol 2020;104:19–22. doi:10.1016/j.pediatrneurol.2019.11.007

doi: 10.1016/j.pediatrneurol.2019.11.007

Reddy AT, Strother DR, Judkins AR, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the Children’s Oncology Group trial ACNS0333. J Clin Oncol Off J Am Soc Clin Oncol 2020;38(11):1175–1185. doi:10.1200/JCO.19.01776

doi: 10.1200/JCO.19.01776

Ho B, Johann PD, Grabovska Y, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus. Neuro-Oncol 2020;22(5):613–624. doi:10.1093/neuonc/noz235

doi: 10.1093/neuonc/noz235

Merchant TE, Bendel AE, Sabin ND, et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J Clin Oncol Off J Am Soc Clin Oncol 2019;37(12):974–983. doi:10.1200/JCO.18.01765

doi: 10.1200/JCO.18.01765

Saleh AH, Samuel N, Juraschka K, et al. The biology of ependymomas and emerging novel therapies. Nat Rev Cancer 2022;22(4):208–222. doi:10.1038/s41568-021-00433-2

doi: 10.1038/s41568-021-00433-2

Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol (Berl) 2017;133(1):5–12. doi:10.1007/s00401-016-1643-0

doi: 10.1007/s00401-016-1643-0

Maintenance chemotherapy or observation following induction chemotherapy and radiation therapy in treating patients with newly diagnosed ependymoma. Accessed October 12, 2023. https://clinicaltrials.gov/ct2/show/NCT01096368

Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med Off J Am Coll Med Genet 2022;24(9):1967–1977. doi:10.1016/j.gim.2022.05.007

doi: 10.1016/j.gim.2022.05.007

Halliday D, Parry A, Evans DG. Neurofibromatosis type 2 and related disorders. Curr Opin Oncol 2019;31(6):562–567. doi:10.1097/CCO.0000000000000579

doi: 10.1097/CCO.0000000000000579

Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol (Berl) 2020;139(4):643–665. doi:10.1007/s00401-019-02029-5

doi: 10.1007/s00401-019-02029-5

Evans DGR, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res Off J Am Assoc Cancer Res 2017;23(12):e54–e61. doi:10.1158/1078-0432.CCR-17-0590

doi: 10.1158/1078-0432.CCR-17-0590

Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primer 2019;5(1):75. doi:10.1038/s41572-019-0125-9

doi: 10.1038/s41572-019-0125-9

Apps JR, Carreno G, Gonzalez-Meljem JM, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol (Berl) 2018;135(5):757–777. doi:10.1007/s00401-018-1830-2

doi: 10.1007/s00401-018-1830-2

Whelan R, Prince E, Gilani A, Hankinson T. The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment. J Clin Med 2020;9(2):519. doi:10.3390/jcm9020519

doi: 10.3390/jcm9020519

Coy S, Rashid R, Lin JR, et al. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro-Oncol 2018;20(8):1101–1112. doi:10.1093/neuonc/noy035

doi: 10.1093/neuonc/noy035

Prieto R, Pascual JM, Subhi-Issa I, et al. Predictive factors for craniopharyngioma recurrence: a systematic review and illustrative case report of a rapid recurrence. World Neurosurg 2013;79(5-6):733–749. doi:10.1016/j.wneu.2012.07.033

doi: 10.1016/j.wneu.2012.07.033

Kilday JP, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro-Oncol 2017;19(10):1398–1407. doi:10.1093/neuonc/nox056

doi: 10.1093/neuonc/nox056

Goldman S, Pollack IF, Jakacki RI, et al. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a pediatric brain tumor consortium report. Neuro-Oncol 2020;22(11):1696–1704. doi:10.1093/neuonc/noaa119

doi: 10.1093/neuonc/noaa119

Gittleman H, Cioffi G, Vecchione-Koval T, et al. Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. J Neurooncol 2019;143(2):251–260. doi:10.1007/s11060-019-03173-4

doi: 10.1007/s11060-019-03173-4

Frappaz D, Dhall G, Murray MJ, et al. EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults. Neuro-Oncol 2022;24(4):516–527. doi:10.1093/neuonc/noab252

doi: 10.1093/neuonc/noab252

Takami H, Ichimura K. Biomarkers for risk-based treatment modifications for CNS germ cell tumors: updates on biological underpinnings, clinical trials, and future directions. Front Oncol 2022;12:982608. doi:10.3389/fonc.2022.982608

doi: 10.3389/fonc.2022.982608

Nakamura H, Takami H, Yanagisawa T, et al. The Japan Society for Neuro-oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors. Neuro-Oncol 2022;24(4):503–515. doi:10.1093/neuonc/noab242

doi: 10.1093/neuonc/noab242

Takami H, Fukuoka K, Fukushima S, et al. Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium. Neuro-Oncol 2019;21(12):1565–1577. doi:10.1093/neuonc/noz139

doi: 10.1093/neuonc/noz139

Taylor JW. Neurologic complications of conventional chemotherapy and radiation therapy. Continuum (Minneap Minn) 29;6 (Neuro-oncology):1809–1826.

Wang N. Neurologic complications of cancer immunotherapy. Continuum (Minneap Minn) 29;6 (Neuro-oncology):1827–1843.

Armstrong C, Sun LR. Neurological complications of pediatric cancer. Cancer Metastasis Rev 2020;39(1):3–23. doi:10.1007/s10555-020-09847-0

doi: 10.1007/s10555-020-09847-0

FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. FDA Published online September 20, 2022. Accessed October 12, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sodium-thiosulfate-reduce-risk-ototoxicity-associated-cisplatin-pediatric-patients

Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2014;32(9):949–959. doi:10.1200/JCO.2013.53.0808

doi: 10.1200/JCO.2013.53.0808

Bowers DC, Verbruggen LC, Kremer LCM, et al. Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2021;22(5):e196–e206. doi:10.1016/S1470-2045(20)30688-4

doi: 10.1016/S1470-2045(20)30688-4

Upadhyay R, Yadav D, Venkatesulu BP, et al. Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: A systematic review and meta-analysis. Front Oncol 2022;12:893855. doi:10.3389/fonc.2022.893855

doi: 10.3389/fonc.2022.893855

Bojaxhiu B, Ahlhelm F, Walser M, et al. Radiation necrosis and white matter lesions in pediatric patients with brain tumors treated with pencil beam scanning proton therapy. Int J Radiat Oncol Biol Phys 2018;100(4):987–996. doi:10.1016/j.ijrobp.2017.11.037

doi: 10.1016/j.ijrobp.2017.11.037

Kralik SF, Ho CY, Finke W, et al. Radiation necrosis in pediatric patients with brain tumors treated with proton radiotherapy. AJNR Am J Neuroradiol 2015;36(8):1572–1578. doi:10.3174/ajnr.A4333

doi: 10.3174/ajnr.A4333

Hall MD, Bradley JA, Rotondo RL, et al. Risk of radiation vasculopathy and stroke in pediatric patients treated with proton therapy for brain and skull base tumors. Int J Radiat Oncol Biol Phys 2018;101(4):854–859. doi:10.1016/j.ijrobp.2018.03.027

doi: 10.1016/j.ijrobp.2018.03.027

Murphy ES, Xie H, Merchant TE, et al. Review of cranial radiotherapy-induced vasculopathy. J Neurooncol 2015;122(3):421–429. doi:10.1007/s11060-015-1732-2

doi: 10.1007/s11060-015-1732-2

Nordstrom M, Felton E, Sear K, et al. Large vessel arteriopathy after cranial radiation therapy in pediatric brain tumor survivors. J Child Neurol 2018;33(5):359–366. doi:10.1177/0883073818756729

doi: 10.1177/0883073818756729

Hersh DS, Moore K, Nguyen V, et al. Evaluation and treatment of children with radiation-induced cerebral vasculopathy. J Neurosurg Pediatr Published online September 20, 2019:1–9. doi:10.3171/2019.7.PEDS19188

doi: 10.3171/2019.7.PEDS19188

Sporns PB, Fullerton HJ, Lee S, et al. Childhood stroke. Nat Rev Dis Primer 2022;8(1):12. doi:10.1038/s41572-022-00337-x

doi: 10.1038/s41572-022-00337-x

Hudson MM, Bhatia S, Casillas J, Landier W; Section on Hematology/Oncology, Children’s Oncology Group, American Society of Pediatric Hematology/Oncology. Long-term follow-up care for childhood, adolescent, and young adult cancer survivors. Pediatrics 2021;148(3):e2021053127. doi:10.1542/peds.2021-053127

doi: 10.1542/peds.2021-053127

Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, version 5.0. Monrovia, CA: Children’s Oncology Group; 2018. Available on line: www.survivorshipguidelines.org

Winter SF, Loebel F, Loeffler J, et al. Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro-Oncol 2019;21(9):1118–1130. doi:10.1093/neuonc/noz048

doi: 10.1093/neuonc/noz048

Baroni LV, Alderete D, Solano-Paez P, et al. Bevacizumab for pediatric radiation necrosis. Neuro-Oncol Pract 2020;7(4):409–414. doi:10.1093/nop/npz072

doi: 10.1093/nop/npz072

Williams AM, Cheung YT, Hyun G, et al. Childhood neurotoxicity and brain resilience to adverse events during adulthood. Ann Neurol 2021;89(3):534–545. doi:10.1002/ana.25981

doi: 10.1002/ana.25981

Schulte F, Kunin-Batson AS, Olson-Bullis BA, et al. Social attainment in survivors of pediatric central nervous system tumors: a systematic review and meta-analysis from the Children’s Oncology Group. J Cancer Surviv Res Pract 2019;13(6):921–931. doi:10.1007/s11764-019-00808-3

doi: 10.1007/s11764-019-00808-3

Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncol 2013;15(10):1429–1437. doi:10.1093/neuonc/not114

doi: 10.1093/neuonc/not114

Ayoub R, Ruddy RM, Cox E, et al. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med 2020;26(8):1285–1294. doi:10.1038/s41591-020-0985-2

doi: 10.1038/s41591-020-0985-2

Carlson-Green B, Puig J, Bendel A. Feasibility and efficacy of an extended trial of home-based working memory training for pediatric brain tumor survivors: a pilot study. Neuro-Oncol Pract 2017;4(2):111–120. doi:10.1093/nop/npw015

doi: 10.1093/nop/npw015

Peterson RK, Longo C, Cunningham T, et al. Impact of home-based cognitive or academic intervention on working memory and mathematics outcomes in pediatric brain tumor survivors: the Keys to Succeed pilot randomized controlled clinical trial. Child Neuropsychol J Norm Abnorm Dev Child Adolesc 2022;28(8):1116–1140. doi:10.1080/09297049.2022.2061933

doi: 10.1080/09297049.2022.2061933

Kralik SF, Mereniuk TR, Grignon L, et al. Radiation-induced cerebral microbleeds in pediatric patients with brain tumors treated with proton radiation therapy. Int J Radiat Oncol Biol Phys 2018;102(5):1465–1471. doi:10.1016/j.ijrobp.2018.07.2016

doi: 10.1016/j.ijrobp.2018.07.2016

Roddy E, Sear K, Felton E, et al. Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro-Oncol 2016;18(11):1548–1558. doi:10.1093/neuonc/now163

doi: 10.1093/neuonc/now163

Morrison MA, Hess CP, Clarke JL, et al. Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: a 7 T MRI study in 113 adult patients with brain tumors. J Magn Reson Imaging JMRI 2019;50(3):868–877. doi:10.1002/jmri.26651

doi: 10.1002/jmri.26651

Gastelum E, Sear K, Hills N, et al. Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. J Child Neurol 2015;30(7):842–849. doi:10.1177/0883073814544364

doi: 10.1177/0883073814544364

Dominguez M, Malani R. Stroke-like migraine attacks after radiation therapy (SMART) syndrome: a comprehensive review. Curr Pain Headache Rep 2021;25(5):33. doi:10.1007/s11916-021-00946-3

doi: 10.1007/s11916-021-00946-3

Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2019;25(8):2560–2574. doi:10.1158/1078-0432.CCR-18-0432

doi: 10.1158/1078-0432.CCR-18-0432

Li L, Zhu X, Qian Y, et al. Chimeric antigen receptor T-cell therapy in glioblastoma: current and future. Front Immunol 2020;11:594271. doi:10.3389/fimmu.2020.594271

doi: 10.3389/fimmu.2020.594271

Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a Phase 1 Dose-Escalation Trial. JAMA Oncol 2017;3(8):1094–1101. doi:10.1001/jamaoncol.2017.0184

doi: 10.1001/jamaoncol.2017.0184

Vitanza NA, Johnson AJ, Wilson AL, et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 2021;27(9):1544–1552. doi:10.1038/s41591-021-01404-8

doi: 10.1038/s41591-021-01404-8

Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022;603(7903):934–941. doi:10.1038/s41586-022-04489-4

doi: 10.1038/s41586-022-04489-4

Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol Off J Eur Soc Med Oncol 2021;32(1):34–48. doi:10.1016/j.annonc.2020.10.478

doi: 10.1016/j.annonc.2020.10.478

Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 2020;4(13):3123–3127. doi:10.1182/bloodadvances.2020002328

doi: 10.1182/bloodadvances.2020002328

Wehrli M, Gallagher K, Chen YB, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer 2022;10(1):e003847. doi:10.1136/jitc-2021-003847

doi: 10.1136/jitc-2021-003847

Diagnostic criteria update - The Children’s Tumor Foundation | Children’s Tumor Foundation. Accessed October 12, 2023. https://www.ctf.org/understanding-nf/nf-criteria-2#